The investment is estimated at EUR335,000.
The net profit of Antibiotice Iasi rose 11.2% on the year to 25.75 million lei (EUR5.8 million) in the first half, helped by higher sales. In January through June 2011, Antibiotice reported a net profit of RON23.14 million.
The company’s majority holder is Romania’s Health Ministry, with a 53% stake, while investment fund SIF Oltenia (SIF5. RO) holds a 10% stake.
Antibiotice is the second-largest nystatin maker in the world, with a 35% market share, according to company information.